Needham & Company Upgrades ResMed (RMD) to Buy; 'New Patient Starts Improving and Product Cycle Likely'
Tweet Send to a Friend
(Updated - March 16, 2021 7:10 AM EDT)Needham & Company analyst Michael Matson upgraded ResMed (NYSE: RMD) from Hold to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
